Evidence map›Paper›PMID 33859800›Full record

ArticleACS medicinal chemistry letters2021

Discovery of the First Orally Available, Selective K

Andrew M Griffin, Kristopher M Kahlig, Robert John Hatch, Zoë A Hughes, Mark L Chapman, Brett Antonio, Brian E Marron, Marion Wittmann, Gabriel Martinez-Botella

Open access · greenAbstract read
In one paragraph

Article in ACS medicinal chemistry letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.

  1. New use for an old drug: quinidine in KCNT1-related epilepsy therapy.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023
    Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Journal of medicinal chemistry · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Reduction ofFrontiers in neuroscience · 2023
    Article
  17. Article
  18. Review
  19. Double-edged Role of KCurrent neuropharmacology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Andrew M GriffinPraxis Precision Medicines, Research Innovation, Cambridge, Massachusetts 02142, United States.
Kristopher M KahligPraxis Precision Medicines, Research Innovation, Cambridge, Massachusetts 02142, United States.
Robert John HatchPraxis Precision Medicines, Research Innovation, Cambridge, Massachusetts 02142, United States.
Zoë A HughesPraxis Precision Medicines, Research Innovation, Cambridge, Massachusetts 02142, United States.
Mark L ChapmanICAGEN, Durham, North Carolina 27703, United States.
Brett AntonioICAGEN, Durham, North Carolina 27703, United States.
Brian E MarronPraxis Precision Medicines, Research Innovation, Cambridge, Massachusetts 02142, United States.
Marion WittmannPraxis Precision Medicines, Research Innovation, Cambridge, Massachusetts 02142, United States.
Gabriel Martinez-BotellaPraxis Precision Medicines, Research Innovation, Cambridge, Massachusetts 02142, United States.
Praxis (United States) · USFlorey Institute of Neuroscience and Mental Health · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The gene

Identifiers

PMID33859800
PMCPMC8040054
OpenAlexW3134473474

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.